Targeting Isocitrate Dehydrogenase (IDH) in Solid Tumors: Current Evidence and Future Perspectives

Area of Science:

• Biochemistry
• Oncology
• Molecular Biology

Background:

• Isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) enzymes are critical for cellular metabolism, differentiation, and stress response.
• Mutations in IDH1 and IDH2 are implicated in the development and progression of various solid tumors, serving as important prognostic and classification markers.
• Elevated D-2-hydroxyglutarate (D-2-HG) levels in tumors and serum can indicate the presence of IDH-mutant tumors.

Purpose of the Study:

• To provide an overview of IDH mutations in solid tumors.
• To review current and emerging IDH-targeted treatments and clinical trial results.
• To discuss future perspectives, including circulating biomarkers and radiomics.

Main Methods:

• Literature review of IDH mutations in solid tumors.
• Analysis of current therapeutic strategies targeting IDH mutations.
• Examination of clinical trial data for IDH-targeted therapies.

Main Results:

• IDH mutations are significant in glioma, cholangiocarcinoma, and chondrosarcoma.
• D-2-HG is a potential diagnostic biomarker for IDH-mutant tumors.
• Clinical trials are evaluating targeted therapies focusing on neomorphic activity, epigenetic effects, and combination strategies.

Conclusions:

• IDH mutations are crucial in solid tumor development and treatment strategies.
• Targeted therapies for IDH mutations are advancing, with a focus on novel mechanisms and combinations.
• Future research directions include circulating biomarkers and radiomic features for enhanced diagnostics and treatment monitoring.